Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test  by Regan, B.C et al.
Vision Research 38 (1998) 3427–3431
Colour discrimination thresholds in Parkinson’s disease: results
obtained with a rapid computer-controlled colour vision test
B.C. Regan a,*, N. Freudenthaler b, R. Kolle b, J.D. Mollon a, W. Paulus b
a Department of Experimental Psychology, Uni6ersity of Cambridge, Downing St., Cambridge CB2 3EB, UK
b Abteilung Klinische Neurophysiologie, Georg-August-Uni6ersita¨t, Go¨ttingen, Germany
Received 10 July 1997
Abstract
A dysfunction of dopaminergic retinal neurons is thought to occur in Parkinson’s disease, manifesting itself in impaired
performance on various visual discrimination tasks. We have investigated whether differences in colour discrimination could
readily be detected between a normal group and a Parkinsonian group, using a computer-controlled test of colour vision.
Although some individual Parkinsonian patients showed an abnormal elevation of colour discrimination thresholds, there was no
significant difference between the normal group and the Parkinsonian group. © 1998 Elsevier Science Ltd. All rights reserved.
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1. Introduction
1.1. Disturbance to 6isual function in Parkinson’s
disease
Disturbances to visual function have repeatedly been
reported in patients with Parkinson’s disease (PD),
including longer latencies for VEPs [1], reduced sensi-
tivity to flicker [2], and reduced contrast sensitivity
[2,3], particularly for spatial frequencies above 4.8 c:d.
It has also been reported that colour vision is impaired
in PD [4,5] and recent work has suggested that these
disturbances to colour vision affect predominantly the
short-wave (S) cone pathway [6,7].
1.2. The retinal dopamine hypothesis
It has been argued that these visual deficits arise at
least in part from dopamine deficiency in the retina [8].
The chemical MPTP (1-methyl, 4-phenyl, 1-2-5-6-te-
trahydropyridine) produces a parkinsonian syndrome
in monkeys. Following MPTP treatment, the latency
and amplitude of VEPs and pattern ERGs to grating
stimuli are altered in monkeys, but recover on adminis-
tration of L-DOPA with carbidopa, suggesting that the
abnormalities arise from dopamine deficiency. That the
deficit is at least partly retinal is suggested by the effect
of intravitreal injection of the dopaminergic neurotoxin
6-hydroxydopamine (6-OHDA), which causes the same
VEP and pattern ERG abnormalities as systemic
MPTP [8].
There are thought to be at least two classes of
dopaminergic neuron in the mammalian retina: do-
paminergic amacrine cells and interplexiform cells [9]
although Dacey [10] has argued that these represent a
single cell type. Interplexiform cells may be concerned
with determining the dimensions of receptive fields [11]
and it has been speculated that the abnormalities in
spatial vision observed in PD arise from abnormal
photopic centre-surround interactions [8]. Haug et al.
[7] suggested that the influence of PD on colour percep-
tion is most noticeable in signals carried by the S-cone
pathway, because the S-cones are widely separated. The
small bistratified ganglion cells, which are the morpho-
logical substrate of the S-cone pathway [12] have much
larger receptive fields than the midget ganglion cells,
and may be more dependent upon long-range spatial
interactions mediated by dopaminergic interplexiform
or amacrine cells.
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1.3. Purpose
The purpose of the current study was twofold: to
attempt to replicate the finding that Parkinson’s disease
predominantly affects the S-cone pathway, and to test
whether a rapid computer-controlled colour vision test
was able to distinguish between PD patients and
controls.
2. Methods
2.1. Subjects
Patients with PD were recruited at the Elena-Klinik,
Kassel, in Germany, where they were receiving therapy
as in-patients for short periods. For controls, we re-
cruited the older staff members of the clinic, and
spouses of the PD patients. Before beginning the com-
puter test, we tested subjects with the Ishihara plates,
and measured visual acuity. The following exclusion
criteria were applied: congenital red-green colour vision
defects, visual acuity below 6:9 in both eyes, history of
diabetes, or senile dementia. All patients were receiving
antiparkinsonian medication. We tested a total of 28
patients and 17 controls. The mean age of the PD
group was 64.8 years (S.D. 6.8 years) and of the control
group was 59.3 years (S.D. 9.0 years). All patients and
controls gave their informed consent to participate in
this study.
2.2. Computer-controlled colour 6ision test
Colour discrimination thresholds were measured us-
ing a computerized test that has been described in detail
elsewhere [13–15]. The test stimulus consists of spa-
tially discrete patches of varying size and luminance,
presented on a black background (Fig. 1(a)). The lumi-
nance of each individual patch varied randomly be-
tween 8 and 18 cd m2 from trial to trial. The majority
of patches constituted the field and were of a single
neutral chromaticity (x, y0.333, 0.333) which re-
mained constant across trials. A subset of patches
formed the target, having the form of a C. The chro-
maticity of the target patches differed from that of the
field patches, and was varied along a line in colour
space on successive trials, according to a staircase pro-
cedure. The outer diameter of the target C subtended
4.3° of visual angle and the inner diameter 2.2°; the gap
subtended 1.0°. The orientation of the target was varied
randomly from trial to trial, with the gap lying at the
top, bottom, left or right. Because Parkinson’s disease
is characterised by difficulty in initiating voluntary
movements, it was decided that the subjects should
indicate verbally the orientation of the C, the experi-
menter pressing a button on their behalf to indicate
their response. Each stimulus was presented for a max-
imum of 8 s; if the subject did not respond in that time,
an incorrect response was recorded. Discrimination was
probed along two lines in colour space (Fig. 1(b)) a
tritan axis, and a constant blue (red–green) axis. Each
of these axes corresponds to one of the two pathways
thought to carry chromatic information in the early
visual system [16,17]. Trials on the two staircases were
randomly interleaved.
The stimuli were generated using an Acorn A5000
computer, and presented on a Sony GDM-1936 Multi-
scan monitor in a darkened room. The Acorn system
allowed the output of each gun of the monitor to be
specified with a precision of 8 bits, which is adequate
for measuring thresholds of normal subjects under our
experimental conditions [15]. The monitor was cali-
brated with a Minolta CS-100 chroma-meter.
3. Results
The results of the test have been plotted in Fig. 2.
Because our patient and control groups were not per-
fectly matched in age, thresholds have been plotted
against age separately for the two axes (Fig. 2(b,c)) as
well as the two axes against each other (Fig. 2(a)).
3.1. Correlations between age and thresholds
There is a statistically significant correlation between
age and discrimination thresholds on the tritan axis of
colour space for both PD patients (Spearman’s rs
0.529, PB0.01, 1-tailed test) and controls (rs0.492,
PB0.05). There is a significant correlation between age
and discrimination threshold on the constant-blue axis
of colour space for PD patients (rs0.376, PB0.05)
but not for controls (rs0.242). The correlation be-
tween tritan thresholds and age is unsurprising and may
reflect yellowing of the crystalline lens with age [18].
There is also a statistically significant correlation be-
tween thresholds on the two axes amongst both PD
patients (rs0.645, PB0.01)and controls (rs0.539,
PB0.05).
3.2. Comparison of PD patients and controls
A Mann-Whitney U test showed no significant differ-
ence in thresholds on either axis of colour space be-
tween PD patients and controls. It is true that a small
number of PD patients had threshold scores outside the
range of scores achieved by normal controls. However,
the majority of PD patients showed no apparent im-
pairment of colour vision on our test; and those few
patients who did show elevated thresholds distinguished
themselves from controls more on the constant-blue
axis of colour space than the tritan axis.
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Fig. 1. (a) Schematic illustration of the stimulus used in our test. We have indicated patches of a target chromaticity by shading them a darker
grey than the patches of the field. (b) A section of the u %, 6% colour diagram showing the two directions probed in the test. The triangle represents
the gamut of the monitor.
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Fig. 2. Results of the test. The units for the threshold scores are thousandths of u %, 6% units. (a) Thresholds on the tritan axis plotted against
thresholds on the constant-blue axis. (b) Thresholds on the tritan axis plotted against age. (c) Thresholds on the constant-blue axis plotted against
age.
4. Discussion
The initial studies suggesting an impairment of
colour discrimination in Parkinson’s disease [4,5] used
the Farnsworth-Munsell 100-hue test. The PD pa-
tients in these studies showed apparently severe im-
pairments in discrimination (Price et al. [4] obtained
mean error scores of 238.3 in PD patients and 73.1 in
controls), a result in striking contrast to our own
finding. There is an obvious explanation for this dif-
ference when one considers the nature of the
Farnsworth-Munsell test, which requires the patient
to make repeated movements whilst rearranging 85
coloured chips into a smoothly graduated colour se-
ries. Given that one of the characteristic symptoms of
PD is difficulty in initiating voluntary movements, it
is difficult to conceive of a more inappropriate test of
colour vision for use with PD patients, and it is per-
haps no surprise that the patients in these studies
showed such apparently severe impairments. Likewise,
the claim of Bu¨ttner et al. [19] that L-DOPA im-
proves colour vision in Parkinson’s disease may well
be an artefact of the alleviation of motor symptoms
by L-DOPA.
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However, it is less easy to explain the discrepancy
between the present results and those of Haug et al. [6],
who found that PD patients differed significantly from
controls on the tritan axis, and whose task identifica-
tion of letters defined by chromaticity differences on a
computer monitor-was in many respects comparable to
the present task; and the two tests would be expected to
have similar sensitivity. Haug et al. [7] found thresholds
elevated on both protan and tritan axes using static
sinusoidal gratings, but for displacement and motion
thresholds it was the tritan axis that gave reliably
significant results. In both these studies, as in the
present one, the patients were receiving antiparkinso-
nian medication and thus this is unlikely to be the
source of the discrepancy.
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